Addus HomeCare Corp
No SEC Form 4 filings for $ADUS in the last 30 days.
Addus HomeCare (NASDAQ: ADUS) reported Q2 CY2026 results. Revenue rose 8% year on year to $377.4 million, matching Wall Street expectations. Non-GAAP adjusted EPS was $1.73, up from $1.49 a year earlier and 1.9% above consensus. Analysts expect full-year EPS to rise from $6.68 to $7.20.
Addus HomeCare Corp (ADUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_997368.htm EXHIBIT 99.1 ex_997368.htm Exhibit 99.1 Contacts: Brian W. Poff Dru Anderson Executive Vice President, Chief Financial Officer FINN Partners Addus HomeCare Corporation (615) 324-7346 (469) 535-8200 dru.anderson@finnpartners.com investorrelations@addus.com
Addus HomeCare (NASDAQ: ADUS) is set to report Q2 results Monday after market hours. The company previously missed revenue expectations, with Q1 revenues of $363.6 million, up 7.7% YoY, while EPS beat. For Q2, analysts expect 7.7% revenue growth. The average analyst price target is $133 versus $115.48.
Over the past 7 days, alphai's AI scored 3 news stories mentioning ADUS (Addus HomeCare Corp). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent ADUS coverage spans financial news, earnings and corporate actions.
In-line revenue with a modest EPS beat suggests limited upside surprise, but the stock sold off 2.6% post-results, implying investors wanted stronger growth or margin expansion.
Q2 beat-style operating momentum (revenue growth, higher adjusted EBITDA, rising net income per share) supports a constructive near-term earnings multiple and margin narrative.
This is an earnings preview with consensus and recent miss history, so the trade is about whether revenue growth re-accelerates or misses again.
Analyst target increase is a modest positive signal, but the maintained Underweight rating tempers upside expectations into the next earnings window.
This is a routine corporate governance update (board/auditor/comp advisory vote) with no new operating or financial guidance.
alphai scores every news story that mentions ADUS with an AI model for sentiment and relevance, and aggregates insider trades from Addus HomeCare Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Addus HomeCare (NASDAQ: ADUS) reported Q2 CY2026 results. Revenue rose 8% year on year to $377.4 million, matching Wall Street expectations. Non-GAAP adjusted EPS was $1.73, up from $1.49 a year earlier and 1.9% above consensus. Analysts expect full-year EPS to rise from $6.68 to $7.20.
4 min readAddus HomeCare Corp (ADUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_997368.htm EXHIBIT 99.1 ex_997368.htm Exhibit 99.1 Contacts: Brian W. Poff Dru Anderson Executive Vice President, Chief Financial Officer FINN Partners Addus HomeCare Corporation (615) 324-7346 (469) 535-8200 dru.anderson@finnpartners.com investorrelations@addus.com
4 min readAddus HomeCare (NASDAQ: ADUS) is set to report Q2 results Monday after market hours. The company previously missed revenue expectations, with Q1 revenues of $363.6 million, up 7.7% YoY, while EPS beat. For Q2, analysts expect 7.7% revenue growth. The average analyst price target is $133 versus $115.48.
4 min readAddus HomeCare (NASDAQ:ADUS) is covered by Barclays, which raised its price target to $96 from $92 on July 8 and kept an Underweight rating. Barclays adjusted targets for U.S. healthcare facilities and managed care coverage ahead of fiscal Q2 earnings. In Q1 ended March 31, 2026, ADUS reported net services revenue of $363.6M (+7.7%), net income of $25.1M, and adjusted EBITDA of $44.5M (+9.7%).
3 min readAddus HomeCare Corp (ADUS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. adus20260610_8k.htm false 0001468328 0001468328 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event report
2 min readAddus HomeCare Corporation reported strong Q4 and full-year 2025 results, with net income rising to US$95.91 million and diluted EPS to US$5.22. The company's adjusted Q4 EPS of US$1.77 and improved operating margins indicate increased efficiency, supporting the investment thesis for home and community-based care. Despite these positive results, the article suggests investors should consider ongoing risks such as potential reimbursement cuts and labor costs against the company's strong performance.
3 min readAddus HomeCare (ADUS) possesses solid growth attributes, which could help it handily outperform the market.
2 min readInvestors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Addus HomeCare ( ADUS Quick QuoteADUS - ) and U.S. Physical Therapy ( USPH Quick QuoteUSPH - ) . But which of these two stocks offers value investors a better bang for their buck ...
4 min readA large exercise of company stock options by Darby Anderson, EVP at Addus HomeCare ( NASDAQ:ADUS ) was disclosed in a new SEC filing on November 20, as part of an insider exercise. What Happened: A Form 4 filing from the U.S.
4 min readQuest Diagnostics, DaVita, Addus HomeCare, and The Pennant Group are positioned to benefit from telehealth, AI adoption, and rising demand in the $747B home healthcare market.
3 min read
